Supernus Announces Preliminary Second Quarter 2020 Revenue
11 août 2020 16h30 HE
|
Supernus Pharmaceuticals, Inc.
Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million, an 11% increase over...
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
26 juin 2020 18h29 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
09 juin 2020 15h46 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at the Jefferies Virtual Health Care Conference
27 mai 2020 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®
15 mai 2020 16h15 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2020 Financial Results
05 mai 2020 18h46 HE
|
Supernus Pharmaceuticals, Inc.
First quarter total revenue of $95.0 million, an 11% increase over 2019First quarter net product sales of $92.5 million, an 11% increase over 2019First quarter operating earnings of $29.0 million, a...
Supernus to Acquire CNS Portfolio from US WorldMeds
28 avr. 2020 17h00 HE
|
Supernus Pharmaceuticals, Inc.
Expands and strengthens neurology portfolio with three marketed CNS products and late-stage pipelineDiversifies revenue and operating cash flow base with 2019 net sales of approximately $150 million...
Supernus to Host First Quarter Results Earnings Conference Call
24 avr. 2020 16h30 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
21 avr. 2020 16h15 HE
|
Supernus Pharmaceuticals, Inc.; Navitor Pharmaceuticals, Inc.
Companies to Collaborate on Phase II Development for NV-5138 in DepressionNV-5138 is a Novel First-in-Class Activator of mTORC1Supernus Receives Exclusive Option to License or Acquire NV-5138 Prior to...
Supernus Provides Business Update
30 mars 2020 17h20 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...